Endometriosis

Breaking period stigmas: SOGC marks World Menstrual Hygiene Day championing access to affordable period products, open dialogue

Retrieved on: 
Dienstag, Mai 28, 2024
Steps, Paper, Private sector, Hygiene, Poverty, Endometriosis, Woman, Norm (mathematics), Health, Life, Public, Menstruation, School, Taboo, Birth control

However, limited access and costs associated with menstrual health needs are an all-too-common challenge for women and girls around the world.

Key Points: 
  • However, limited access and costs associated with menstrual health needs are an all-too-common challenge for women and girls around the world.
  • That’s why the Society of Obstetricians and Gynaecologists of Canada (SOGC) joins the global community in marking World Menstrual Hygiene Day 2024, aimed at breaking the silence, raising awareness and changing negative social norms surrounding menstrual health.
  • As the national voice of women’s health, the SOGC is committed to addressing menstrual hygiene and advocating for menstrual equity.
  • In Canada, many women and girls still experience period poverty, lacking access to affordable menstrual hygiene products.

Dr. Stacey A. Scheib Joins The Fertility Institute

Retrieved on: 
Dienstag, Mai 28, 2024
Women, General Health, Health, Parenting, Family, Baby, Maternity, Consumer, LGBTQ+, Partnership, Patient, PCOS, Teratoma, Endometriosis, Drexel University, Cyst, Fertility, Pelvic pain, Uterine fibroid, Gynaecology, Adenomyosis, Hysterectomy, MIGS, Multimedia, Polyp (medicine), Johns Hopkins, Birth control

The Fertility Institute of New Orleans is pleased to welcome Dr. Stacey A. Scheib as a Minimally Invasive Gynecological Surgeon.

Key Points: 
  • The Fertility Institute of New Orleans is pleased to welcome Dr. Stacey A. Scheib as a Minimally Invasive Gynecological Surgeon.
  • She is now scheduling new patient appointments at the New Orleans (Metairie) and Mandeville locations of The Fertility Institute.
  • (Photo: Business Wire)
    The addition of Dr. Scheib to the Fertility Institute expands the service offerings we provide for complex cases.
  • The Fertility Institute Medical Director, Dr. Warren Jay Huber, expressed the impact of having a skilled surgeon such as Dr. Scheib, stating, “Dr.

EDAP Reports First Quarter 2024 Financial Results

Retrieved on: 
Donnerstag, Mai 16, 2024
Patient, TMS, Endometriosis, USD, Randomized controlled trial, AUA, Food, Investment, Diagnosis, FDA, EDT, DIE, Comparison, Oncology, Prostate cancer, Growth, Clinical trial, EUR, Operating cost, Woman, EDAP

Company to host conference call and webcast today, May 16th, at 8:30 a.m. EDT

Key Points: 
  • Company to host conference call and webcast today, May 16th, at 8:30 a.m. EDT
    LYON, France, May 16, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the first quarter of 2024.
  • As noted, our Phase 3 study completed patient enrollment in January, and we expect topline results from this study in the second half of 2024.
  • Operating loss for the first quarter of 2024 was EUR 4.8 million (USD 5.2 million), compared to an operating loss of EUR 6.6 million (USD 7.1 million) in the first quarter of 2023.
  • A conference call and webcast to discuss the first quarter 2024 financial results will be hosted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer.

Ezra Partners with Princeton Radiology for Proactive, Whole-Body MRI Screenings to Support Earlier Cancer Detection

Retrieved on: 
Mittwoch, Mai 15, 2024
Partnership, Patient, Fatty liver disease, Endometriosis, MRI, Disease, Radiology, Prostate, Cancer, Physician, Medical imaging

NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Ezra , the healthcare AI startup transforming early cancer detection through full body MRI screening, today announced a new partnership with Princeton Radiology Associates, based in Princeton, New Jersey.

Key Points: 
  • NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Ezra , the healthcare AI startup transforming early cancer detection through full body MRI screening, today announced a new partnership with Princeton Radiology Associates, based in Princeton, New Jersey.
  • With this new relationship, Princeton Radiology will add Ezra‘s AI-powered whole-body MRI screening technology to its extensive offering of imaging services throughout its freestanding office network in Central and Northern NJ – bringing advanced early cancer detection technology to New Jersey residents.
  • Ezra’s end-to-end cancer screening platform monitors for cancer and 500+ other conditions – including fatty liver disease, endometriosis, and aneurysm – in up to 13 organs.
  • Patients can now schedule an Ezra full-body MRI scan at all Princeton Radiology locations.

Ironwood Pharmaceuticals Reports First Quarter 2024 Results

Retrieved on: 
Donnerstag, Mai 9, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, PS, Phase, Capsule, The Lancet, Gastrointestinal disease, Safety, AbbVie, Food, Interstitial cystitis, SBS, Depreciation, Interest, Trial of the century, Endometriosis, Research, Hepatology, IQVIA, Disease, Autoimmune disease, Patient, Liver, Acquisition, Short bowel syndrome, Constipation, DDW, STARS, Primary biliary cholangitis, Bank statement, Adjustment, Standard of care, Clinical trial, PBC, GAAP, Food and Drug Administration, Income tax, Ageing, Pharmaceutical industry

LINZESS commercial margin, excluding the gross-to-net change in estimate, was 71% in the first quarter of 2024, compared to 73% in the first quarter of 2023.

Key Points: 
  • LINZESS commercial margin, excluding the gross-to-net change in estimate, was 71% in the first quarter of 2024, compared to 73% in the first quarter of 2023.
  • Total revenue in the first quarter of 2024 was $74.9 million, compared to $104.1 million in the first quarter of 2023.
  • Operating expenses in the first quarter of 2024 were $63.9 million, compared to $44.0 million in the first quarter of 2023.
  • Ironwood generated $45.0 million in cash from operations in the first quarter of 2024, compared to $80.2 million in cash from operations in the first quarter of 2023.

National Poll Shows Women Are Missing Out on Vacations, Work, and Social Events Due to Gynecological Conditions

Retrieved on: 
Donnerstag, Mai 2, 2024
Generation Z, Polycystic ovary syndrome, Public opinion, Premenstrual syndrome, PMS, Infant, Advertising, Woman, Health, Research, Generation X, Marketing, OnePoll, Endometriosis, ESOMAR, Depression, Market Research Society, Mental, Silent Generation, Millennials, Generation, Quality of life, Anxiety, Menopause, Urinary tract infection, Opinion, Knowledge, Nursing

"Millions of women silently struggle every day with gynecological conditions, some as common as PMS and UTIs," said Liz Weir, chief marketing officer at LevLane.

Key Points: 
  • "Millions of women silently struggle every day with gynecological conditions, some as common as PMS and UTIs," said Liz Weir, chief marketing officer at LevLane.
  • Reasons for absence: Premenstrual/Period symptoms (26%), UTIs (18%) and endometriosis (6%) were common causes for missing work.
  • Baby boomers had the highest cancellation rate due to gynecological conditions, while Generation Z had the lowest.
  • This random double-opt-in survey of 1,000 American women was commissioned by LevLane between April 12 and April 16, 2024.

Hera Biotech Announces Positive Interim Results From Endometriosis Diagnostic Study

Retrieved on: 
Dienstag, April 23, 2024
General Health, Professional Services, Consumer, Technology, Artificial Intelligence, Genetics, Health Technology, Data Analytics, Clinical Trials, Women, Biotechnology, Health, University, Executive, Woman, Hera, Infertility, Endometriosis, Uterus, Female, PCR, DRS, Disease, Therapy, Patient, CSO, Diagnosis, Biomarker, AUC

Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDx™ endometriosis diagnostic test.

Key Points: 
  • Hera Biotech is pleased to report the interim results for its proof-of-concept multi-center clinical trial of the MetriDx™ endometriosis diagnostic test.
  • “This result suggests that Hera’s molecular diagnostic test has the potential to replace surgical diagnosis and greatly improve the woefully inadequate state of endometriosis diagnosis and treatment that exists today,” said Hera Biotech CEO Somer Baburek.
  • Hera is focused on a tissue based approach for diagnosing endometriosis, utilizing a pipelle to non-surgically obtain endometrial cells for analysis.
  • Based on these promising results, Hera intends to bring a rapid bulk PCR endometriosis diagnostic test to market in 2025.

GE HealthCare Introduces AI-Enhanced Voluson Signature 20 and 18 Ultrasound Systems to Advance Women’s Health Imaging

Retrieved on: 
Donnerstag, April 18, 2024
Other Health, Consumer, Medical Devices, Technology, Hospitals, Artificial Intelligence, Surgery, Cardiology, Women, Biotechnology, Medical Supplies, Health, International Society, GE HealthCare, Pregnancy, Woman, AI, Endometriosis, Artificial intelligence, Workflow, Pelvic floor, Motion, Female, Automation, Patient, Diagnosis, Anomaly scan, Medical imaging

GE HealthCare (Nasdaq: GEHC) today announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health.

Key Points: 
  • GE HealthCare (Nasdaq: GEHC) today announced the launch of the Voluson Signature 20 and 18 ultrasound systems, which comprehensively integrate artificial intelligence (AI), advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions impacting women’s health.
  • These latest systems combine high-performance hardware with flexible scalable software to help increase clinicians’ confidence in their diagnostic and treatment determinations.
  • "We've seen huge advancements in ultrasound technology, including the use of AI, resulting in a new era of ultrasound scanning.
  • For more information on the Voluson Signature 20 and 18 devices, visit https://www.gehealthcare.com/products/ultrasound/voluson/voluson-signatu... and https://www.gehealthcare.com/products/ultrasound/voluson/voluson-signatu... .

NYC Occult Inguinal Hernia Specialist Dr. Mark Zoland Shines at 2024 Endometriosis Summit

Retrieved on: 
Donnerstag, April 25, 2024
Pelvis, Groin, Therapy, Abdomen, Radiology, Hernia, NFL, Suite, MLS, Surgeon, Endometriosis, NBA, Patient, Coccydynia, MLB, MRI, NHL, Multimedia

NEW YORK, April 25, 2024 /PRNewswire-PRWeb/ -- The Endometriosis Summit, recently held on March 8th, 2024, in Orlando, FL, drew medical professionals, surgeons, physical therapists and patients from around the world. Renowned for his expertise in diagnosing and understanding occult hernias in the abdomen and pelvis, Dr. Mark Zoland's lecture was met with praise from attendees. It focused on the intricate nature of diagnosing occult hernias when traditional radiologists and doctors are unable to do so. His groundbreaking insights shed light on this often-overlooked condition, providing invaluable knowledge to the medical community. The 2024 Endometriosis Summit boasted an impressive lineup of interactive workshops, lab training and research-based panels. The topics covered ranged from gaslighting, treatments and tailbone pain to the intriguing world of the microbiome. Attendees also had the opportunity to participate in video sessions, surgical didactics and the highly anticipated patient and practitioner town meeting. This year, the summit introduced a groundbreaking addition to its program - a live-time imaging lab on the latest techniques in MRI and ultrasound for endometriosis. This cutting-edge feature allowed medical professionals to stay at the forefront of the field, ensuring the highest quality of care for patients.

Key Points: 
  • Esteemed specialist, Dr. Mark Zoland, recently captivated audiences as a guest speaker at the highly anticipated 2024 Endometriosis Summit.
  • Renowned for his expertise in diagnosing and understanding occult hernias in the abdomen and pelvis, Dr. Mark Zoland 's lecture was met with praise from attendees.
  • "It was an honor to be part of the 2024 Endometriosis Summit and share my expertise on occult hernias.
  • "It was an honor to be part of the 2024 Endometriosis Summit and share my expertise on occult hernias.

University of Arizona Student Receives SBB Research Group Foundation STEM Scholarship

Retrieved on: 
Montag, April 22, 2024
Emerald, University, Learning, Endometriosis, Research, STEM, Student

CHICAGO, April 22, 2024 /PRNewswire-PRWeb/ -- The SBB Research Group Foundation named Emerald Bell a recipient of its STEM scholarship. The $2,500 award empowers students to create value for society by pursuing higher learning through interdisciplinary combinations of Science, Technology, Engineering, and Mathematics (STEM).

Key Points: 
  • CHICAGO, April 22, 2024 /PRNewswire-PRWeb/ -- The SBB Research Group Foundation named Emerald Bell a recipient of its STEM scholarship.
  • The $2,500 award empowers students to create value for society by pursuing higher learning through interdisciplinary combinations of Science, Technology, Engineering, and Mathematics (STEM).
  • Emerald Bell, a fourth-year graduate student, studies nursing at the University of Arizona.
  • "Emerald's research is fascinating, and I'm so happy that we can support her in her graduate work," said Matt Aven, co-founder and board member of the SBB Research Group Foundation.